Literature DB >> 12865429

The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein.

Ramesh Hegde1, Srinivasa M Srinivasula, Pinaki Datta, Muniswamy Madesh, Richard Wassell, ZhiJia Zhang, NaEun Cheong, Julie Nejmeh, Teresa Fernandes-Alnemri, Shin-ichi Hoshino, Emad S Alnemri.   

Abstract

Smac/Diablo and HtrA2/Omi are inhibitors of apoptosis (IAP)-binding proteins released from the mitochondria of human cells during apoptosis and regulate apoptosis by liberating caspases from IAP inhibition. Here we describe the identification of a proteolytically processed isoform of the polypeptide chain-releasing factor GSPT1/eRF3 protein, which functions in translation, as a new IAP-binding protein. In common with other IAP-binding proteins, the processed GSPT1 protein harbors a conserved N-terminal IAP-binding motif (AKPF). Additionally, processed GSPT1 interacts biochemically with IAPs and could promote caspase activation, IAP ubiquitination and apoptosis. The IAP-binding motif of the processed GSPT1 is absolutely required for these activities. Our findings are consistent with a model whereby processing of GSPT1 into the IAP-binding isoform could potentiate apoptosis by liberating caspases from IAP inhibition, or target IAPs and the processed GSPT1 for proteasome-mediated degradation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865429     DOI: 10.1074/jbc.M303179200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Controlling TRAIL-mediated caspase-3 activation.

Authors:  O Micheau; D Mérino
Journal:  Leukemia       Date:  2004-10       Impact factor: 11.528

2.  Involvement of human release factors eRF3a and eRF3b in translation termination and regulation of the termination complex formation.

Authors:  Céline Chauvin; Samia Salhi; Catherine Le Goff; Wildriss Viranaicken; Dialo Diop; Olivier Jean-Jean
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  An unconventional IAP-binding motif revealed by target-assisted iterative screening (TAIS) of the BIR3-cIAP1 domain.

Authors:  Alexei Kurakin; Dale E Bredesen
Journal:  J Mol Recognit       Date:  2007 Jan-Feb       Impact factor: 2.137

Review 4.  Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.

Authors:  Casey W Wright; Colin S Duckett
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

5.  GGCn polymorphism of eRF3a/GSPT1 gene and breast cancer susceptibility.

Authors:  Mahboobe Miri; Simin Hemati; Foruzan Safari; Manoochehr Tavassoli
Journal:  Med Oncol       Date:  2011-11-19       Impact factor: 3.064

6.  Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice.

Authors:  L Miguel Martins; Alastair Morrison; Kristina Klupsch; Valentina Fedele; Nicoleta Moisoi; Peter Teismann; Alejandro Abuin; Evelyn Grau; Martin Geppert; George P Livi; Caretha L Creasy; Alison Martin; Iain Hargreaves; Simon J Heales; Hitoshi Okada; Sebastian Brandner; Jörg B Schulz; Tak Mak; Julian Downward
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

7.  Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types.

Authors:  J Malta-Vacas; C Aires; P Costa; A R Conde; S Ramos; A P Martins; C Monteiro; M Brito
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

8.  Specificity profiling of dual specificity phosphatase vaccinia VH1-related (VHR) reveals two distinct substrate binding modes.

Authors:  Rinrada Luechapanichkul; Xianwen Chen; Hashem A Taha; Shubham Vyas; Xiaoyan Guan; Michael A Freitas; Christopher M Hadad; Dehua Pei
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

9.  Molecular basis of eRF3 recognition by the MLLE domain of poly(A)-binding protein.

Authors:  Guennadi Kozlov; Kalle Gehring
Journal:  PLoS One       Date:  2010-04-14       Impact factor: 3.240

Review 10.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.